Dr. Puyuan Xing 邢镨元
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of lung cancer, including chemotherapy, targeted therapy, and immunotherapy.
Dr. Xing holds a doctorate in oncology and serves as a graduate supervisor. Clinical work focuses on medical oncology and clinical research of new anti-tumor drugs. Research interests include individualized treatment for lung cancer.
Name order: in Chinese the family name comes first (Xing Puyuan). Papers usually list the name as Puyuan Xing or Xing P.
Selected publications
147 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- Neuro Oncol, 2026 (senior author): Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights. PubMed 42899412
- Signal Transduct Target Ther, 2026 (senior author): Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma. PubMed 42493498
- BMC Cancer, 2026 (senior author): Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma. PubMed 41981503
- Transl Lung Cancer Res, 2026 (senior author): Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China. PubMed 41659264
- Front Microbiol, 2025 (senior author): Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients. PubMed 41311499
- Oncologist, 2025 (first author): Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study. PubMed 40349136
- Thorac Cancer, 2025 (senior author): A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC. PubMed 40355260
- Transl Lung Cancer Res, 2025 (senior author): Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer. PubMed 40386714
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion